BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Everyone’s a winner: UCB bids $2.1B for Ra Pharma, adds to MG pipeline
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Everyone’s a winner: UCB bids $2.1B for Ra Pharma, adds to MG pipeline
Oct. 11, 2019
By
Cormac Sheridan
No Comments
DUBLIN – Shares in Ra Pharmaceuticals Inc. doubled Thursday as UCB SA made a $48-per-share bid that values the company at about $2.5 billion, or about $2.1 billion net of Ra’s cash.
BioWorld
Deals and M&A